Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - October 2017

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Beclometasone / formoterol / glycopyrronium inhaler (Trimbow®) has been accepted for restricted use as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. The restriction limits use to patients with a forced expiratory volume in one second less than 50% predicted normal.

Opicapone (Ongentys®) has been rejected for use as an adjunctive therapy to preparations of levodopa / DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations. The manufacturer did not make a submission to the SMC and therefore the product cannot be recommended.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - October 2017' on Email Share 'SMC Update - October 2017' on Delicious Share 'SMC Update - October 2017' on Digg Share 'SMC Update - October 2017' on Facebook Share 'SMC Update - October 2017' on Google+ Share 'SMC Update - October 2017' on reddit Share 'SMC Update - October 2017' on StumbleUpon Share 'SMC Update - October 2017' on Twitter

atomic-wealth

No Comments to “SMC Update - October 2017”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,665 spam comments.

atomic-wealth
fond-illness
summer